What makes us unique?
We are an ambitious biopharmaceutical company with cutting-edge technology capable of creating the next generation of protease inhibitors therapeutics
Research
Our claim
Many diseases are developed due to the lack of certain compounds that regulate proteolytic pathways
Our goal
We discover the regulatory mechanism and based on those discoveries, we develop new medicines
Our approach
Understanding the mechanism of cell self-regulation of the relevant proteolytic pathway
Our technology
AI-powered medicinal chemistry
R&D
Neurodegenerative diseases
We have developed new inhibitors of proteases that play crucial role in neurodegenerative disesases
Cancer research
We have developed new computational technology for identifying causal influences of nutrition & microbiome on cancer growth
Team
Dr. Ewelina Weglarz-Tomczak
Science & LeadershipFounder, Chief Scientific Officer
Iffat Rose Gill
Business & StrategyBusiness Developer
Caroline van Wingerde
Research & DevelopmentResearch Associate
Stacy Maciel
Research & DevelopmentResearch Associate
Advisory Board
Prof. Anna Maria Colangelo
Advisor in NeurobiologyUniversity of Milano-Bicocca
Prof. Marten Smidt
Advisor in NeuroscienceUniversity of Amsterdam
Assoc. Prof. Jakub Tomczak
Principal Scientist, AIEindhoven University of Technology
Dr. Marc Roelofs
Investment ManagerUvA AMC HvA Ventures Holding BV